EKF.GB EKF Diagnostics Holdings PLC

TIDMEKF

RNS Number : 9264Z

EKF Diagnostics Holdings PLC

20 September 2022

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

Dividend Timetable

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business , confirms that, further to the passing of the resolution at the AGM, a cash dividend of 1.2p per ordinary share will be paid in relation to its 2021 results as per the below timetable. The dividend will be paid to shareholders, on the register at close of business on 4 November 2022, on 1 December 2022.

The dividend timetable dates are detailed below:

 
 Ex-dividend     3 November 2022 
  date: 
 Record date:    4 November 2022 
 Payment date:   1 December 2022 
 
 
EKF Diagnostics Holdings plc                                       www.ekfdiagnostics.com 
Mike Salter, CEO / Marc Davies, CFO                              Tel: +44 (0)29 2071 0570 
 
Singer Capital Markets (Nominated Adviser                        Tel: +44 (0)20 7496 3000 
 & Joint Broker) 
Aubrey Powell / George Tzimas / Oliver 
 Platts 
 
Investec Bank plc (Joint Broker)                                 Tel: +44 (0)20 7597 4000 
Gary Clarence / Daniel Adams / Ben Farrow 
 
Walbrook PR Limited                        Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com 
Paul McManus / Lianne Applegarth                           Mob: +44 (0)7980 541 893 / +44 
                                                                          (0)7584 391 303 
 

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:

 
 Point-of-Care            Providing a portfolio of Point-of-Care analysers and 
                           consumables, particularly for use in the area of Hematology 
                           and Diabetes, for use in hospital and research laboratories, 
                           doctor's offices, blood banks and for in-field anaemia 
                           screening programmes. EKF has an estimated 80,000 
                           hemoglobin, hematocrit, HbA1c, glucose and lactate 
                           analysers in regular use across more than 100 countries. 
 Central Laboratory       Clinical chemistry, Small lab analysers, Centrifuges 
                           Beta-Hydroxybutyrate (<BETA>-HB) LiquiColor , Glycated 
                           Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin 
 Life Sciences            Enzyme fermentation, Custom products and Bulk fermentation 
 Contract Manufacturing   Bulk formulation, Sample collection kits, Private 
                           labelling, Molecular and forensic kits 
 Laboratory Testing       Laboratory testing services certified under the Clinical 
                           Laboratory Improvement Amendments ("CLIA") for high 
                           complexity testing. 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCGPUCPBUPPGQB

(END) Dow Jones Newswires

September 20, 2022 02:01 ET (06:01 GMT)

EKF Diagnostics (AQSE:EKF.GB)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025

EKF Diagnostics (AQSE:EKF.GB)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025